ENTERPRISE VASCULAR RECONSTRUCTION DEVICE AND DELIVERY SYSTEM
Report
- Report Number
- 1058196-2013-00058
- Event Type
- Injury
- Date Received
- February 28, 2013
- Date of Event
- April 2, 2012
- Report Date
- February 7, 2013
- Manufacturer
- CORDIS NEUROVASCULAR, INC.
- Product Code
- NJE
- PMA / PMN Number
- H60001
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FL, US
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
THERE WAS ONE REPORT OF AN IATROGENIC CAROTID-CAVERNOUS FISTULA IN A PATIENT THAT HAD AN UNRUPTURED ANEURYSM. THE MEAN AGE AT TIME OF ENTERPRISE STENT DEPLOYMENT WAS (B)(6) AND WOMEN REPRESENTED 81%OF THE STUDY PATIENTS. THE MAJORITY OF TREATED ANEURYSMS WERE INTERNAL CAROTID ARTERY ANEURYSMS, WITH OPHTHALMIC SEGMENT (26.6%). MEAN ANEURYSM SIZE WAS 9.2 +/- 0.4 MM (MEDIAN, 7.0; RANGE, 1.5-35.0 MM). MEAN PARENT VESSEL SIZE WAS 3.3 +/- 0.1 MM (MEDIAN, 3.3 MM; RANGE, 1.5-5.7MM). THE AUTHORS CONCLUDED THAT ALTHOUGH THE STUDY IS LIMITED IN ITS RETROSPECTIVE NATURE THE ENTERPRISE STENT SYSTEM APPEARS TO BE AN EFFECTIVE, SAFE AND DURABLE TREATMENT FOR INTRACRANIAL ANEURYSMS WHEN USED IN CONJUNCTION WITH COILING. CONCLUSION: INFORMATION VIA A LITERATURE REVIEW WAS NOTED IN FARGEN, KYLE M., ET AL, "LONG-TERM RESULTS OF ENTERPRISE STENT-ASSISTED COILING OF CEREBRAL ANEURYSMS"; NEUROSURGERY VOL. 71, NO. 2, 8-2012. NINE CENTERS PROVIDED DE-IDENTIFIED DATA ON ALL CONSECUTIVE PATIENTS WHO UNDERWENT ENTERPRISE VRD DEPLOYMENT AS PART OF ANEURYSM TREATMENT PRIOR TO MAY 2009; 229 PATIENTS WITH 229 ANEURYSMS WERE INCLUDED IN THE STUDY. THERE WERE THREE DEATHS RELATED TO INTRACRANIAL HEMORRHAGE AND ONE DEATH DUE TO A PERIPROCEDURAL MYOCARDIAL INFARCTION. THERE WERE THREE INTRACRANIAL HEMORRHAGES WITHOUT DEATH OF THE PATIENT. THERE WERE 10 REPORTED THROMBOEMBOLIC EVENTS, 7 REPORTS OF INSTENT RESTENOSIS (3 LESS THAN 50%, 3 APPROXIMATELY 50%, AND ONE GREATER THAN 50%), ATTEMPTED COILING WAS NOT ACCOMPLISHED SECONDARY TO STENT PROLAPSE IN ONE PATIENT, KINKED STENT IN ONE PATIENT AND REPEATED COIL PROLAPSE IN ONE PATIENT. THERE WAS ONE REPORT OF IATROGENIC CAROTID CAVERNOUS FISTULA. THERE IS NO UNIQUE IDENTIFYING PATIENT, TARGET SITE, EVENT DESCRIPTION, OR HOSPITAL INFORMATION. THE MEAN AGE AT TIME OF ENTERPRISE STENT DEPLOYMENT WAS (B)(6) AND WOMEN REPRESENTED 81%OF THE STUDY PATIENTS. THE MAJORITY OF TREATED ANEURYSMS WERE INTERNAL CAROTID ARTERY ANEURYSMS, WITH OPHTHALMIC SEGMENT (26.6%). MEAN ANEURYSM SIZE WAS 9.2 +/- 0.4 MM (MEDIAN, 7.0; RANGE, 1.5-35.0 MM). MEAN PARENT VESSEL SIZE WAS 3.3 +/- 0.1 MM (MEDIAN, 3.3 MM; RANGE, 1.5-5.7MM). THE AUTHORS CONCLUDED THAT ALTHOUGH THE STUDY IS LIMITED IN ITS RETROSPECTIVE NATURE THE ENTERPRISE STENT SYSTEM APPEARS TO BE AN EFFECTIVE, SAFE AND DURABLE TREATMENT FOR INTRACRANIAL ANEURYSMS WHEN USED IN CONJUNCTION WITH COILING. THE DEVICES REMAIN IMPLANTED AND THE LOT NUMBERS ARE NOT KNOWN; THEREFORE A DEVICE HISTORY RECORD REVIEW CANNOT BE COMPLETED. THERE WAS ONE REPORT OF AN IATROGENIC CAROTID-CAVERNOUS FISTULA IN A PATIENT THAT HAD AN UNRUPTURED ANEURYSM. INJURY TO NORMAL VESSELS OR TISSUES IS A KNOWN POTENTIAL ADVERSE EVENT ASSOCIATED WITH THE USE OF THE ENTERPRISE VRD AND THE PROCEDURES THEY ARE USED IN AS OUTLINED IN THE INSTRUCTIONS FOR USE. PROCEDURAL, CLINICAL, AND PATIENT FACTORS MAY HAVE CONTRIBUTED. BASED ON THE LACK OF INFORMATION, NO CONCLUSION CAN BE MADE REGARDING ANY RELATIONSHIP OF THE EVENT TO THE ENTERPRISE VRD. THEREFORE, NO CORRECTIVE ACTIONS WILL BE TAKEN AT THIS TIME. THIS IS ONE OF NINE REPORTS INVOLVED WITH THIS LITERATURE ARTICLE, WHICH IS ASSOCIATED WITH MFG REPORTS 1058196-2013-00055, 1058196-2013-00056, 1058196-2013-00057, 1058196-2013-00058, 1058196-2013-00059, 1058196-2013-00060, 1058196-2013-00061, 1058196-2013-00062, AND 1058196-2013-00063.
INFORMATION VIA A LITERATURE REVIEW WAS NOTED IN FARGEN, KYLE M., ET AL, "LONG-TERM RESULTS OF ENTERPRISE STENT-ASSISTED COILING OF CEREBRAL ANEURYSMS"; NEUROSURGERY VOL. 71, NO. 2, 8-2012. NINE CENTERS PROVIDED DE-IDENTIFIED DATA ON ALL CONSECUTIVE PATIENTS WHO UNDERWENT ENTERPRISE VRD DEPLOYMENT AS PART OF ANEURYSM TREATMENT PRIOR TO MAY 2009; 229 PATIENTS WITH 229 ANEURYSMS WERE INCLUDED IN THE STUDY.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 86486 | ENTERPRISE VASCULAR RECONSTRUCTION DEVICE AND DELIVERY SYSTEM | CNV ENTERPRISE SES (NJE) | NJE | CORDIS NEUROVASCULAR, INC. | NA | UNK |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |